Search

Your search keyword '"Gelblum, Daphna Y."' showing total 246 results

Search Constraints

Start Over You searched for: Author "Gelblum, Daphna Y." Remove constraint Author: "Gelblum, Daphna Y."
246 results on '"Gelblum, Daphna Y."'

Search Results

1. Validation of Patient-Reported Outcomes in Patients With Nonmetastatic Breast Cancer Receiving Comprehensive Nodal Irradiation in the RadComp Trial

2. Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial

5. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

6. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation

8. Stereotactic body radiation therapy for sarcoma pulmonary metastases

9. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis

10. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity

11. A Phase 1 Safety Study of Avelumab Plus Stereotactic Body Radiation Therapy in Malignant Pleural Mesothelioma

12. Induction chemotherapy effects on very advanced (T3/T4) human papillomavirus-related oropharyngeal cancer for participation in hypoxia-directed major de-escalation (30 Gy) definitive treatment trial.

13. Determinants of radiation exposure during mobile cone‐beam CT‐guided robotic‐assisted bronchoscopy

14. Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline

15. A Prospective Study on Deep Inspiration Breath Hold Thoracic Radiation Therapy Guided by Bronchoscopically Implanted Electromagnetic Transponders

18. 40 Gray in 5 Fractions for Salvage Reirradiation of Spine Lesions Previously Treated With Stereotactic Body Radiotherapy.

20. An18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy

21. Hypoxia-Directed Treatment of Human Papillomavirus–Related Oropharyngeal Carcinoma

24. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers

25. AB026. Outcomes and toxicities of definitive radiation therapy for unresected thymic malignancies

26. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study

27. Sparing Bilateral Neck Level IB in Oropharyngeal Carcinoma and Xerostomia Outcomes

29. ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy

35. Clinical and Dosimetric Risk Factors Associated with Radiation Induced Lung Toxicities after Multiple Courses of Lung Stereotactic Body Radiation Therapy

36. Dosimetric Comparison of Intensity-Modulated Radiation Therapy (IMRT) and Intensity-Modulated Proton Therapy (IMPT) for a Novel Oral Tongue Avoidance Concept in Low-Risk Squamous Cell Carcinoma of the Oral Tongue

37. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma

38. Analysis of Tumor Mutational Burden, Progression-Free Survival, and Local-Regional Control in Patients with Locally Advanced Non–Small Cell Lung Cancer Treated With Chemoradiation and Durvalumab

41. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy

42. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers

44. Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non–small cell lung cancer (NSCLC) treated with definitive radiation therapy.

45. Safety and efficacy of stereotactic body proton therapy for high-risk lung tumors.

46. Intensity-Modulated Radiation Therapy in Oropharyngeal Carcinoma: Effect of Tumor Volume on Clinical Outcomes

47. Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience

48. Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab

49. Quality of Life Analysis of a Radiation Dose–Escalation Study of Patients With Non–Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial

50. Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK / ROS1 / RET -Rearranged Lung Cancers.

Catalog

Books, media, physical & digital resources